High fragmentation characterizes tumour-derived circulating DNA

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Mouliere, Florent ^a   Robert, Bruno ^b   Peyrotte, Erika ^a   Del Rio, Maguy ^b   Ychou, Marc ^c   Molina, Franck ^a   Gongora, Celine ^b   Thierry, Alain R ^a  

^a National Centre of the Scientific Research/BIO RAD   (France)

^b INSERM   (France)

^c CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; TUMOR DERIVED CIRCULATING DNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CANCER SIZE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DETERMINATION; DNA FRAGMENTATION; FEMALE; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; MOLECULAR SIZE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; TUMOR XENOGRAFT; ANIMAL; BLOOD; COLORECTAL TUMOR; DRUG SCREENING; GENETICS; HEALTH; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

MUS; MUS MUSCULUS;

ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA FRAGMENTATION; DNA, NEOPLASM; FEMALE; HEALTH; HUMANS; MICE; MICE, NUDE; POLYMERASE CHAIN REACTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052436485     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023418     Document Type: Article

References (31)

1. Sawyers CL, (2008) The cancer biomarker problem. Nature 452: 548-552.
2. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, et al. (2002) Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A 99: 9433-9438.
3. Gormally E, Hainaut P, Caboux E, Airoldi L, Autrup H, et al. (2004) Amount of DNA in plasma and cancer risk: a prospective study. Int J Cancer 111: 746-749.
4. Fleischhacker M, Schmidt B, (2007) Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 1775: 181-232.
5. Frattini M, Gallino G, Signoroni S, Balestra D, Lusa L, et al. (2008) Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett 263: 170-181.
6. Schwarzenbach H, Stoehlmacher J, Pantel K, Goekkurt E, (2008) Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann N Y Acad Sci 1137: 190-196.
7. Flamini E, Mercatali L, Nanni O, Calistri D, Nunziatini R, et al. (2006) Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res 12: 6985-6988.
8. Guadalajara H, Dominguez-Berzosa C, Garcia-Arranz M, Herreros MD, Pascual I, et al. (2008) The concentration of deoxyribonucleic acid in plasma from 73 patients with colorectal cancer and apparent clinical correlations. Cancer Detect Prev 32: 39-44.
9. Diehl F, Li M, Dressman D, He Y, Shen D, et al. (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 102: 16368-16373.
10. Holdenrieder S, Holubec L Jr, Topolcan O, Finek J, Stieber P, (2005) Circulating nucleosomes and cytokeratin 19-fragments in patients with colorectal cancer during chemotherapy. Anticancer Res 25: 1795-1801.
11. Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P, (2001) About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 313: 139-142.
12. van der Vaart M, Pretorius PJ, (2008) Circulating DNA. Its origin and fluctuation. Ann N Y Acad Sci 1137: 18-26.
13. Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, et al. (2003) Increased plasma DNA integrity in cancer patients. Cancer Res 63: 3966-3968.
14. Deligezer U, Erten N, Akisik EE, Dalay N, (2006) Circulating fragmented nucleosomal DNA and caspase-3 mRNA in patients with lymphoma and myeloma. Exp Mol Pathol 80: 72-76.
15. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, et al. (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61: 1659-1665.
16. Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, et al. (2010) Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res 38: 6159-6175.
17. Gongora C, Candeil L, Vezzio N, Copois V, Denis V, et al. (2008) Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38. Cancer Biol Ther 7: 822-832.
18. Akagi J, Takai E, Tamori Y, Nakagawa K, Ogawa M, (2001) CA19-9 epitope a possible marker for MUC-1/Y protein. Int J Oncol 18: 1085-1091.
19. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, et al. (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611-622.
20. Ellinger J, Bastian PJ, Haan KI, Heukamp LC, Buettner R, et al. (2008) Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int J Cancer 122: 138-143.
21. Ellinger J, Wittkamp V, Albers P, Perabo FG, Mueller SC, et al. (2009) Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. J Urol 181: 363-371.
22. Ellinger J, Albers P, Muller SC, von Ruecker A, Bastian PJ, (2009) Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker. BJU Int 104: 48-52.
23. Chan KC, Zhang J, Hui AB, Wong N, Lau TK, et al. (2004) Size distributions of maternal and fetal DNA in maternal plasma. Clin Chem 50: 88-92.
24. Mamon H, Hader C, Li J, Wang L, Kulke M, et al. (2008) Preferential amplification of apoptotic DNA from plasma: potential for enhancing detection of minor DNA alterations in circulating DNA. Clin Chem 54: 1582-1584.
25. Schmidt B, Weickmann S, Witt C, Fleischhacker M, (2008) Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease. Ann N Y Acad Sci 1137: 207-213.
26. Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, et al. (2006) Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 24: 4270-4276.
27. Deligezer U, Eralp Y, Akisik EE, Akisik EZ, Saip P, et al. (2008) Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy. Clin Chem Lab Med 46: 311-317.
28. Jung K, Fleischhacker M, Rabien A, (2010) Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature. Clin Chim Acta 411: 1611-1624.
29. Mori S, Sugahara K, Uemura A, Yamada Y, Uzihara K, et al. (2007) The possibility of a valuable resource of circulating DNA for single nucleotide polymorphisms genotyping: the application of a rapid and simple polymerase chain reaction with melting curve analysis for methyltetrahydrofolate reductase polymorphisms. Lab Hematol 13: 1-5.
30. Liu KJ, Brock MV, Shih Ie M, Wang TH, (2010) Decoding circulating nucleic acids in human serum using microfluidic single molecule spectroscopy. J Am Chem Soc 132: 5793-5798.
31. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, et al. (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27: 2091-2096.